Cargando…

Use of sustained release dextroamphetamine for the treatment of stimulant use disorder in the setting of injectable opioid agonist treatment in Canada: a case report

BACKGROUND: For people with opioid use disorder who are not responding to oral opioid agonist treatment, evidence supports the effectiveness of injectable opioid agonist treatment with injectable hydromorphone (an opioid analgesic) and diacetylmorphine (pharmaceutical grade heroin). While this treat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Palis, Heather, MacDonald, Scott, Jun, Jennifer, Oviedo-Joekes, Eugenia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8136105/ https://www.ncbi.nlm.nih.gov/pubmed/34016137 http://dx.doi.org/10.1186/s12954-021-00500-9

Ejemplares similares

Exploring the effectiveness of dextroamphetamine for the treatment of stimulant use disorder: a qualitative study with patients receiving injectable opioid agonist treatment
por: Palis, Heather, et al.
Publicado: (2021)

Adverse Events During Treatment Induction With Injectable Diacetylmorphine and Hydromorphone for Opioid Use Disorder
por: Oviedo-Joekes, Eugenia, et al.
Publicado: (2019)

Feasibility of Applying the Life History Calendar in a Population of Chronic Opioid Users to Identify Patterns of Drug Use and Addiction Treatment
por: Fikowski, Jill, et al.
Publicado: (2014)

Men’s and women’s response to treatment and perceptions of outcomes in a randomized controlled trial of injectable opioid assisted treatment for severe opioid use disorder
por: Palis, Heather, et al.
Publicado: (2017)

Building healthcare provider relationships for patient-centered care: A qualitative study of the experiences of people receiving injectable opioid agonist treatment
por: Marchand, Kirsten, et al.
Publicado: (2020)

Changes in daily dose in open-label compared to double-blind: The role of clients’ expectations in injectable opioid agonist treatment
por: Blawatt, Sarin, et al.
Publicado: (2023)

Take home injectable opioids for opioid use disorder during and after the COVID-19 Pandemic is in urgent need: a case study
por: Oviedo-Joekes, Eugenia, et al.
Publicado: (2021)

The association between nicotine dependence and physical health among people receiving injectable diacetylmorphine or hydromorphone for the treatment of chronic opioid use disorder()
por: Palis, Heather, et al.
Publicado: (2018)

Sex work involvement among women with long-term opioid injection drug dependence who enter opioid agonist treatment
por: Marchand, Kirsten, et al.
Publicado: (2012)

Feasibility of Testing Client Preferences for Accessing Injectable Opioid Agonist Treatment (iOAT): A Pilot Study
por: Dobischok, Sophia, et al.
Publicado: (2022)

The Impact of Injectable Opioid Agonist Treatment (iOAT) on Involvement in Criminalized Activities: A Secondary Analysis from a Clinical Trial in Vancouver, BC
por: Dobischok, Sophia, et al.
Publicado: (2023)

The Role of Gender in Factors Associated With Addiction Treatment Satisfaction Among Long-Term Opioid Users
por: Marchand, Kirsten, et al.
Publicado: (2015)

“As long as that place stays open, I’ll stay alive”: Accessing injectable opioid agonist treatment during dual public health crises
por: Jaffe, Kaitlyn, et al.
Publicado: (2023)

Dextroamphetamine Treatment for Children With Hypothalamic Obesity
por: van Schaik, Jiska, et al.
Publicado: (2021)

Dextroamphetamine Treatment in Children With Hypothalamic Obesity
por: van Schaik, Jiska, et al.
Publicado: (2022)

Clients’ experiences on North America’s first take-home injectable opioid agonist treatment (iOAT) program: a qualitative study
por: Oviedo-Joekes, Eugenia, et al.
Publicado: (2023)

Dextroamphetamine-Amphetamine Augmentation in the Treatment of Treatment-Resistant Depression
por: Small, Tyler M, et al.
Publicado: (2022)

The SALOME study: recruitment experiences in a clinical trial offering injectable diacetylmorphine and hydromorphone for opioid dependency
por: Oviedo-Joekes, Eugenia, et al.
Publicado: (2015)

Stimulant use disorder diagnosis and opioid agonist treatment dispensation following release from prison: a cohort study
por: Palis, Heather, et al.
Publicado: (2022)

The impact of relaxing restrictions on take-home doses during the COVID-19 pandemic on program effectiveness and client experiences in opioid agonist treatment: a mixed methods systematic review
por: Adams, Alison, et al.
Publicado: (2023)

Interactions Between Opioids and Dextroamphetamine on Locomotor Activity: Influence of an Opioid's Relative Efficacy at the Mu Receptor
por: Smith, Mark A., et al.
Publicado: (2022)

Opioid agonist treatment (OAT) experiences and release plans among federally incarcerated individuals with opioid use disorder (OUD) in Ontario, Canada: a mixed-methods study
por: Russell, Cayley, et al.
Publicado: (2022)

Incorporating prescription psychostimulants into the continuum of care for people with stimulant use disorder in Canada
por: Palis, Heather, et al.
Publicado: (2023)

Differential long-term outcomes for voluntary and involuntary transition from injection to oral opioid maintenance treatment
por: Oviedo-Joekes, Eugenia, et al.
Publicado: (2014)

A critical analysis of user satisfaction surveys in addiction services: opioid maintenance treatment as a representative case study
por: Trujols, Joan, et al.
Publicado: (2014)

Service delivery models for injectable opioid agonist treatment in Canada: 2 sequential environmental scans
por: Eydt, Erin, et al.
Publicado: (2021)

Central serous chorioretinopathy associated with Adderall (dextroamphetamine-amphetamine) and topical steroid use
por: Alsberge, Joseph B., et al.
Publicado: (2022)

Barriers and facilitators to opioid agonist treatment (OAT) engagement among individuals released from federal incarceration into the community in Ontario, Canada
por: Russell, Cayley, et al.
Publicado: (2022)

Provider experiences with relaxing restrictions on take-home medications for opioid use disorder during the COVID-19 pandemic: A qualitative systematic review
por: Adams, Alison, et al.
Publicado: (2023)

Client satisfaction among participants in a randomized trial comparing oral methadone and injectable diacetylmorphine for long-term opioid-dependency
por: Marchand, Kirsten I, et al.
Publicado: (2011)

Peer-led safer supply and opioid agonist treatment medication distribution: a case study from rural British Columbia
por: Scow, Marnie, et al.
Publicado: (2023)

Conceptualizing patient-centered care for substance use disorder treatment: findings from a systematic scoping review
por: Marchand, Kirsten, et al.
Publicado: (2019)

Alcohol use in opioid agonist treatment
por: Nolan, Seonaid, et al.
Publicado: (2016)

Negative Impact of Amphetamine-Type Stimulant Use on Opioid Agonist Treatment Retention in Ontario, Canada
por: Morin, Kristen A., et al.
Publicado: (2021)

Prescription de psychostimulants aux personnes présentant un trouble lié à l’utilisation de stimulants dans le continuum de soins au Canada
por: Palis, Heather, et al.
Publicado: (2023)

Trends in Rates of Opioid Agonist Treatment and Opioid-Related Deaths for Youths in Ontario, Canada, 2013-2021
por: Rosic, Tea, et al.
Publicado: (2023)

Patient-centred care for addiction treatment: a scoping review protocol
por: Marchand, Kirsten, et al.
Publicado: (2018)

Measuring treatment attrition at various stages of engagement in Opioid Agonist Treatment in Ontario Canada using a cascade of care framework
por: Tahsin, Farah, et al.
Publicado: (2022)

The authors respond to letters on using prescribed psychostimulants to treat stimulant use disorder
por: Palis, Heather N., et al.
Publicado: (2023)

First-line opioid agonist treatment as prevention against assisting others in initiating injection drug use: A longitudinal cohort study of people who inject drugs in Vancouver, Canada
por: Bouck, Zachary, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_e88k7iacjrs8rep9f2dbf3aja0